Skip to main content
Download PDF

Downregulation of lncRNA Miat contributes to the protective effect of electroacupuncture against myocardial fibrosis

Chinese Medicine volume 17, Article number: 57 (2022) Cite this article

Abstract

Background

Myocardial fibrosis changes the structure of myocardium, leads to cardiac dysfunction and induces arrhythmia and cardiac ischemia, threatening patients’ lives. Electroacupuncture at PC6 (Neiguan) was previously found to inhibit myocardial fibrosis. Long non-coding RNAs (lncRNAs) play a variety of regulatory functions in myocardial fibrosis, but whether electroacupuncture can inhibit myocardial fibrosis by regulating lncRNA has rarely been reported.

Methods

In this study, we constructed myocardial fibrosis rat models using isoproterenol (ISO) and treated rats with electroacupuncture at PC6 point and non-point as control. Hematoxylin–eosin, Masson and Sirius Red staining were performed to assess the pathological changes and collagen deposition. The expression of fibrosis-related markers in rat myocardial tissue were detected by RT-qPCR and Western blot. Miat, an important long non-coding RNA, was selected to study the regulation of myocardial fibrosis by electroacupuncture at the transcriptional and post-transcriptional levels. In post-transcriptional level, we explored the myocardial fibrosis regulation effect of Miat on the sponge effect of miR-133a-3p. At the transcriptional level, we studied the formation of heterodimer PPARG–RXRA complex and promotion of the TGF-β1 transcription.

Results

Miat was overexpressed by ISO injection in rats. We found that Miat can play a dual regulatory role in myocardial fibrosis. Miat can sponge miR-133a-3p in an Ago2-dependent manner, reduce the binding of miR-133a-3p target to the 3ʹUTR region of CTGF mRNA and improve the protein expression level of CTGF. In addition, it can also directly bind with PPARG protein, inhibit the formation of heterodimer PPARG–RXRA complex and then promote the transcription of TGF-β1. Electroacupuncture at PC6 point, but not at non-points, can reduce the expression of Miat, thus inhibiting the expression of CTGF and TGF-β1 and inhibiting myocardial fibrosis.

Conclusion

We revealed that electroacupuncture at PC6 point can inhibit the process of myocardial fibrosis by reducing the expression of lncRNA Miat, which is a potential therapeutic method for myocardial fibrosis.

Introduction

Myocardial fibrosis refers to the excessive accumulation of collagen fibers in the tissue structure of the myocardium, while its collagen concentration or collagen volume fraction is significantly increases [1, 2]. In recent years, many studies have shown that myocardial fibrosis can occur in many cardiovascular diseases, such as hypertension [3], myocardial infarction [4] and heart failure [5, 6], and can even cause sudden death [7]. Myocardial fibrosis involves a variety of original causes, and its regulatory mechanism is affected by many factors [8,9,10]. Generally speaking, myocardial fibrosis is the result of an imbalance in collagen synthesis and degradation [11,12,13]. Transforming growth factor-β1 (TGF-β1) is a multifunctional protein peptide, which can increase the synthesis of collagen-based interstitial proteins [14, 15]. TGF-β1 can increase the expression of type I and type II collagen mRNA in cultured cells in vitro and increase the stability of type I collagen mRNA [16, 17]. Recent studies have also found that there is a close interaction between TGF-β1 and Ang II [18, 19]. In the course of myocardial fibrosis, Ang II increases the expression of the TGF-β1 gene [20, 21], while TGF-β1 inhibits the degradation of extracellular matrix and increases the expression of extracellular matrix mRNA and protein synthesis [22, 23]. Connective tissue growth factor (CTGF) is a secreted peptide, which is rich in cysteine, widely present in human tissues and organs, and is related to diseases such as atherosclerosis and organ fibrosis [24]. CTGF share many biological functions with TGF-β1, and is the downstream product of TGF-β1 [25, 26]. Its abnormal expression plays an important role in the myocardial fibrosis process [27, 28]. Blocking the expression of TGF-β1 and CTGF or weakening their activity may be an effective means to prevent further development of myocardial fibrosis.

Long non-coding RNA (lncRNA) is defined as an RNA that is more than 200 nucleotides in length but lacks protein coding potential [29,30,31]. LncRNA regulates gene expression at multiple levels, including epigenetics, transcriptional regulation and post-transcriptional regulation [32]. LncRNA plays a key role in the occurrence and development of myocardial fibrosis [33, 34]. However, the mechanisms of lncRNA action in myocardial fibrosis have received relatively limited attention. Recent studies have shown that the lncRNA myocardial infarction associated transcript (Miat) is involved in the pathological process of many diseases, including diabetic retinopathy [35], myocardial infarction [36], microvascular dysfunction [37] and cardiac hypertrophy [38]. LncRNA cardiac hypertrophy-related factor (CHRF) is up-regulated in heart hypertrophy, and CHRF regulates cardiac hypertrophy by targeting miR-489 [39]. Valsartan et al. found that by down-regulating CHRF, it can inhibit the TGF-β signaling pathway and improve doxorubicin-induced heart failure [40].

Recently, researchers have studied the effect of lncRNA PFL on myocardial fibrosis. PFL promotes the cell proliferation and fibrosis of cardiac fibroblasts by acting as a competitive endogenous RNA of let-7d [41]. The lncRNA RASSF1-AS1 encoded by the antisense strand of the RASSF1A gene was significantly overexpressed in the isoproterenol (ISO)-induced mice model. RASSF1-AS1 binds to RASSF1 mRNA to promote NF-κB activation and inhibit the translation of RASSF1A, thus exacerbating myocardial fibrosis in mice, indicating a potential application of RASSF1-AS1 as a therapy target for myocardial fibrosis [42]. The expression of myocardial specific lncRNA Colorectal Neoplasia Differentially Expressed (CRNDE) is negatively correlated with the expression of genes related to myocardial fibrosis. CRNDE suppresses myocardial fibrosis by inhibiting Smad3 [43]. LncRNAs have various effects on myocardial fibrosis, which need to be further studied, the therapeutic methods of regulating lncRNA also need to be further explored.

Currently, there is no therapeutic drug that can effectively control the fibrotic reaction, which is accompanied by many side effects. Therefore, the discovery of alternative therapeutic methods for myocardial fibrosis is of great significance in clinical practice. Electroacupuncture of PC6, either preconditioning or after ischemia–reperfusion injury, reduced mortality in mice [44] and rats [45, 46]. In addition, pretreatment with electroacupuncture at PC6 reduced the size of myocardial infarction caused by coronary artery ligation in rats [47]. Electroacupuncture at PC6 after coronary artery ligation reduced cardiac scar area and improved angiogenesis in rats [48]. Myocardial fibrosis causes abnormalities in the cardiac function, metabolism and conduction, which can lead to heart failure and various arrhythmias [49]. Electroacupuncture at PC6 inhibited myocardial fibrosis on hypertension-induced myocardial fibrosis in spontaneously hypertensive rats (SHRs), which may be mediated by down-regulation of the enhanced Ang II-TGF-β1-CTGF/TNF-α pathway and up-regulation of the reduced MMP-9 expression [50].

In this study, we used ISO to construct rat models with myocardial fibrosis for experimental study, and studied the anti-fibrosis effect of electroacupuncture and its potential mechanism in regulating lncRNA Miat.

Materials and methods

Animals and ethics

Male Sprague-Dawley (SD) rats weighing 250 ± 30 g (SCXK (Chuan) 2015-030; Dashuo Co., Ltd., Chengdu, China) were housed in a controlled condition (12:12 h light: dark cycle, 25 ± 2 °C, 50% ± 5% relative humidity) with food and water ad libitum. All experimental procedures were approved by the Chengdu University of Traditional Chinese Medicine Animal Welfare and Ethics Committee and conformed to the standards of the International Council for Laboratory Animal Science.

Animal model establishment

SD rats were injected with isoproterenol (ISO) to cause myocardial fibrosis due to chronic myocardial ischemia. Male SD rats were randomized into four groups (n = 10): normal saline (NS) control, isoproterenol injection (ISO) group, ISO + electroacupuncture (EA) group and ISO + non-acupoint (NA) control. Isoproterenol (2 mg/kg;) was injected intraperitoneally (i.p.) for 2 weeks, to establish the myocardial fibrosis rat model. Control mice were injected with normal saline at equivalent volume. At the end of each experiment, the rats were sacrificed with high dose of isoflurane.

Electroacupuncture treatment

Prior to electroacupuncture treatment, all rats were restrained using the same method. The animals in both ISO + EA (n = 10) and ISO + NA (n = 10) groups received electroacupuncture treatment for 20 min daily for a total of 2 weeks. Two acupuncture needles (15 mm long and 0.3 mm in diameter) were inserted at a depth of 2–3 mm into the PC6 acupoints with an electrical stimulator (Han’s acupoint nerve stimulator, HANS-200, Nanjing, China) at a frequency of 2/100 Hz and an intensity level of 1 mA for 20 min. Researches on the specificity of acupoints need a contrast of non-acupoint. Select a point at the rat tail as the non-meridian and non-acupoint control point, which can better avoid the meridians and acupoints [46]. Therefore, the same treatments were applied to the base of the tail in the NA group rats. After the treatment, we randomly selected six rats (n = 6) in each group for subsequent experiments.

Histopathological analysis

The heart was fixed in neutral paraformaldehyde solution (4%) (Solarbio, Beijing, China) for tissue fixation. The organs were cut into appropriate sections, washed, dehydrated and embedded to make tissue wax. The samples were then sectioned (4-µm thickness) and separately stained with hematoxylin and eosin (H&E) (Solarbio), Masson trichrome (Solarbio) and Sirius-Red staining (Solarbio), according to the manufacturer’s protocols. To analyze the extent of damage, images were captured using a microscope (Nikon, Japan). The area of damage in the heart tissues was determined using Image J (version 1.8.0) software.

Western blot

For the Western blot analysis, the protein was extracted from the rats’ myocardial tissue using a Tissue Protein Extraction Kit (Beyotime Biotechnology, Shanghai, China) according to the protocol provided by the manufacturer. RIPA lysis buffer (Servicebio, Wuhan, China) was used to extract protein from H9c2 cells. Protein concentrations were quantified using the Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo Fisher Scientific, MA, USA). Total proteins obtained from cardiac tissues were loaded onto 10% sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. After blocking with 5% non-fat milk for 1 h at room temperature, the membranes were incubated at 4 °C overnight with Collagen I, Collagen III, CTGF, TGF-β1, PPARG, RXRA and Actin antibody, which were purchased from ProteinTech (Chicago, IL, USA), and ACTIN was used as the loading control. After washing with Tris-buffered saline/0.1% Tween 20 (TBST) for 5 times, the membranes were incubated with the secondary antibodies for 1 h at room temperature. Goat anti-mouse IgG (Catalogue no. SA00001-1) and goat anti-rabbit IgG (Catalogue no. SA00001-2) antibodies were purchased from ProteinTech (Chicago, IL, USA). Mouse anti-rabbit IgG LCS (Catalogue no. A25022) antibody was purchased from Abbkine (Wuhan, China). Immunoreactive bands were visualized using Immobilon ECL Ultra Western HRP Substrate (Merck, USA). The intensity of the bands was assessed using the Image Lab software from Bio-Rad (Bio-Rad, Hercules, CA, USA).

H9c2 and HEK293 cells culture

H9c2 rat embryonic heart myoblast cells and HEK293 human embryonic kidney epithelial cells were purchased from Procell Life Science Technology Co. Ltd. (Wuhan, China) and cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) (Hyclone, Logan, UT, USA) with 10% fetal bovine serum (FBS; Gibco, USA) and 1% of penicillin–streptomycin (Hyclone). All the cells were incubated in a humidified incubator at 37 °C under an atmosphere of 95% air and 5% CO2.

Isolation of cytoplasmic and nuclear RNA

Nuclear and cytoplasmic components were separated using the Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, Shanghai, China) according to the manufacturer’s instructions. RiboLock RNase Inhibitor 100 U/mL (Thermo) was added to the lysis buffer from the kit before the experiment. The nuclear precipitate was directly resuspended in TRIzol reagent and subjected to RNA extraction.

Plasmids and miRNAs transfection

H9c2 or HEK293 cells were plated in 6-well culture plates at a density of 2 × 105 cells per well for 24 h. Transfections were performed using Lipofectamine® 2000 (Invitrogen, Thermo Fisher Scientific, Inc) according to the manufacturer’s instructions. Plasmid DNA or siRNAs were diluted in Opti-MEM (Gibco, Thermo Fisher Scientific, Inc.) and mixed with pre-prepared solutions of Lipofectamine® 2000 for 5 min at 25 °C. Thereafter, 250 μL of the complex solutions were added to each well, and the cells were slightly agitated to mix. Cells were then incubated for 4–6 h in a humidified incubator (5% CO2, 37 °C) before adding fresh media. Next, transfections were repeated at 24 h intervals (48 h and 72 h, as indicated). The Miat expression plasmid and siRNAs target for lncRNA Miat were designed and purchased from TSINGKE Biological Technology Co., Ltd. Control rno-miRNA (rno-miRNA-NC), rno-mir-133a-3p mimic and rno-mir-133a-3p inhibitors were purchased from RiboBio (Guangzhou, China).

Quantitative reverse transcription-PCR (RT-qPCR)

Total RNA samples were extracted from cultured H9c2 cells or the left ventricular region of the heart using Trizol reagent (Invitrogen, USA). For each sample, 0.5 μg of total RNA was converted to cDNA using a cDNA reverse transcription kit (Thermo). The expression levels of mRNA and miRNA were analyzed by RT-qPCR reactions using the SYBR Green I RT-qPCR Easy™ (Foregene, Chengdu, China) and a BIOER Detection System (Bioer Technology Co. Ltd. Hangzhou, China). The RNA levels of Miat, miR-133a, collagen I (Col I) and collagen III (Col III) were detected by the SYBR Green method. After cyclic responses, cyclic thresholds (Ct) were determined, and the relative quantitative expression levels of Miat, miR-133a and mRNA were calculated using the method of 2−ΔΔCq and normalized to ACTIN or U6 as internal controls. The primer sequences were synthesized by Tsingke, Chengdu. The primers of miR-133a-3p and U6 were purchased from RiboBio (Guangzhou, China). The sequences of the RT-qPCR Primers and siRNA oligonucleotides are listed in Additional file 1: Table S1.

Dual luciferase reporter gene assay

Bioinformatics analysis predicted, as reported in literature, that lncRNA Miat contained a normative binding site for miR-133a-3p. Meanwhile, the analysis also showed that CTGF was a potential target gene of miR-133A-3p. To verify whether they can interact directly, we constructed the recombinant plasmid pmirGLO-CTGF-3ʹUTR (WT) and pmirGLO-CTGF-3ʹUTR (MUT). HEK293 cells were seeded into 24-well plates and co-transfected with luciferase reporter plasmids and miR-133a-3p mimics or miR-NC using Lipofectamine®2000 (Invitrogen) according to the manufacturer’s instructions. At 48 h after transfection, the luciferase activity of each group was detected using the dual luciferase reporter gene assay kit (Keygen, Nanjing, China). To test the TGF-β1 promoter activity, the promoter region of TGF-β1 was inserted into the pGL3 luciferase reporter vector (Progema, Madison, WI, USA). Recombinant Plasmid pGL3-TGF-β1 was extracted using EndoFree Mini Plasmid Kit II (Tiangen, Beijing). To verify the involvement of Miat in regulating TGF-β1 promoter activity, the plasmid pGL3-TGF-β1 (800 ng) was co-transfected with the plasmid PRL-TK (20 ng) using Lipofectamine® 2000 according to the manufacturer’s protocol. At the same time, lncRNA Miat was overexpressed or knockdown as previously described. At 48 h after transfection, luciferase activity was measured using the dual-luciferase reporter gene assay system (Keygen) 3 times in each group.

RNA immunoprecipitation (RIP) and co-immunoprecipitation (co-IP) assays

H9c2 cell lysates from 1 × 106 cells were combined with 1 mL IP buffer (25 mM Tris-Cl [pH 7.4], 150 mM NaCl, 0.5% NP-40, 0.5 mM DTT and 1 × complete protease inhibitors [Roche]) supplemented with 100 U/mL RNase Inhibitor (Thermo) and subjected to immunoprecipitation with 2 μg PPARG antibody or IgG at 4 °C overnight with rotation. The immunoprecipitates were digested with proteinase K (Thermo Scientific), and then the immunoprecipitated RNA was recovered using TRIzol reagent (Thermo Scientific). cDNA was synthesized with primers using the RevertAid RT Kit (Thermo Scientific) and subjected to RT-qPCR for Miat transcripts and miR-133a-3p. For co-immunoprecipitation assays, cell lysates were incubated with PPARG antibody 2 μg overnight at 4 °C, and then with protein A/G plus agarose beads (20 μL/sample) for 1 h at 4 °C. Immunoprecipitants were collected by centrifugation and washed 4 times with lysis buffer, and then the beads were precipitated through centrifugation and re-suspended in 2× SDS loading buffer. The protein present in the co-IP material was examined by Western blot.

Statistical analysis

All data are expressed as the mean ± SD. The significance of differences between two groups was determined using the Student’s unpaired t test. Comparisons between groups were performed using one-way ANOVA (Tukey’s multiple comparisons test). Differences with P < 0.05 were considered to be statistically significant.

Results

Electroacupuncture at PC6 reduces myocardial fibrosis

Injecting ISO can cause myocardial ischemia, resulting in myocardial ischemia injury and myocardial fibrosis [51]. The representative ECG diagrams were selected for the analysis of myocardial ischemia injury. Electroacupuncture at PC6 (ISO + EA) significantly reversed the S-T segment change induced by ISO infusion. Conversely, electroacupuncture of the tail (ISO + NA group) demonstrated no such potential to decrease the S-T segment change (Fig. 1A and B). After 2 weeks of treatment, the hearts were harvested to quantify myocardial fibrosis. We first used HE staining to evaluate the myocardial tissue. Compared with the NA group, myocardial fibers in the ISO model group were deformed and disordered with striated muscle disappeared, cytoplasm was vacuolated to varying degrees, and inflammatory cell infiltration was observed in some myocardial tissues. In addition, the pathological damage of myocardial tissue was partially weakened in the electroacupuncture group, but not significantly weakened in the non-acupoint (NA) group. Masson collagen specific staining (normal myocardium is red, fibrosis area is blue) showed that compared with normal control group, collagen accumulation and the fibrosis area in the model group were significantly increased. In addition, the staining results of Sirius red were similar to those of Masson. Based on these results, we found that electroacupuncture PC6 attenuated myocardial fibrosis.

Fig. 1
figure 1

Effects of the electroacupuncture treatment on ISO-induced myocardial fibrosis. A Representative electrogastrogram (EGG) recordings and B Changes in rat ECG-ST (mV, A) of EGG in NS, ISO, ISO + EA and ISO + NA groups (n = 6 in each group). C Samples of myocardial tissue stained with hematoxylin and eosin (H&E) (bar = 100 μm), Masson’s trichrome (Tricon), and Sirius red. D Percent area fibrosis (Mason staining) and (Sirius staining) in the indicated groups (bar = 50 μm) (n = 6 per group)

Full size image

Involvement of Collagen I/III, CTGF, TGF-b1 in the electroacupuncture-induced antifibrosis effects

The expression of markers related to fibrosis in rat myocardial tissue was detected by RT-qPCR and Western blot. The mRNA expression levels of fibrosis related genes type I collagen, type III collagen, CTGF and TGF-β1 were significantly increased in the ISO rats’ myocardial tissue (Fig. 2A–D). The expression levels of these mRNAs were decreased by electroacupuncture at PC6. Similar results were observed in the expression of fibrosis-related protein, but electroacupuncture in NA had no significant effect (Fig. 2E and F). These results suggest that electroacupuncture at PC6 can inhibit myocardial fibrosis in ISO rats by inhibiting the expression of type I collagen, type III collagen, TGF-β1 and CTGF.

Fig. 2
figure 2

Effects of electroacupuncture on the level of myocardial fibrosis markers. A–D RT-qPCR was performed to determine the mRNA expression of Collagen I, Collagen III, TGF-β1 and CTGF in rat heart tissues (n = 6 rats in each group). E, F Western blot was performed to determine the protein expression of Collagen I, Collagen III, TGF-β1 and CTGF in rat heart tissues, ACTIN was used as loading control. Results are presented as mean ± SD. *P < 0.05, **P < 0.01

Full size image

Electroacupuncture can regulate the expression of lncRNA Miat

The rat Miat gene locus location is 12q16, and oriented sense configuration (Fig. 3A). Prediction of the Miat translation capacity using CNIT program [52] showed that the Miat protein-coding ability was poor (Fig. 3B). Using lncLocator program [53] to predict the Miat subcellular localization, the results showed that most of Miat is located in the nucleus (> 90%), and a small amount is located in the cytoplasm (> 7%) (Fig. 3C). Our nuclear separation experiments showed that the abundance of Miat was much higher in the nuclear fraction compared with the cytoplasmic fraction (Fig. 3D). We also examined the effects of electroacupuncture on Miat and found that electroacupuncture at PC6 decreased the expression level of Miat, which caused overexpression by ISO injection, while electroacupuncture at non-point had no significant change (Fig. 3E).

Fig. 3
figure 3

Electroacupuncture reduced the expression of lncRNA Miat. A Schematic illustration of the genomic locus of Miat and neighboring genes on rat chromosome 12q16. B Miat was predicted to be of a poor protein coding capacity. The RNA sequences of Miat, MALAT1, Actb and Gapdh were evaluated by the CNIT program. MALAT1 served as a control non-coding transcript, while Gapdh and Actb served as control protein coding transcripts. C Subcellular localization of Miat precited by the lncLocator program. D Nuclear separation experiments showed the subcellular localization of Miat. Actin mRNA was used as a control for the cytoplasmic fraction; U6 mRNA was used as a control for the nuclear fraction. E The relative expression levels of Miat were detected in different groups. Values are expressed as the means ± SD (n = 3), *P < 0.05, **P < 0.01

Full size image

LncRNA Miat sponges miR-133a-3p in an Ago2-dependent manner

Bioinformatics predictions using the Targetscan website [54] indicated that the Miat sequence contained the putative binding site of miR-133a-3p (Fig. 4A and B). In addition, it has been previously reported that Miat is the direct target of miR-133a-3p [55], miRNA exists in the form of miRNA ribonucleoprotein complex (miRNP), which contains Ago2, the core component of RNA-induced silencing complex [56]. MicroRNAs bind to their targets and cause translational repression and/or RNA degradation in an Ago2-dependent manner [57]. To determine whether lncRNA Miat binds to miR-133a-3p in this manner, RNA-binding protein immunoprecipitation (RIP) was performed in H9c2 cardiomyocytes using Ago2 antibody (Fig. 4C). It was found that Miat and miR-133a-3p preferentially enriched miRNP containing Ago2 compared with IgG immunoprecipitates. In addition, after mimic-133a-3p was transfected with H9c2 cells, more Miat were employed by Ago2 (Fig. 4D). We further determined that Miat can bind to miR-133a-3p through an Ago2-based manner.

Fig. 4
figure 4

Miat sponges miR-133a in an Ago2-dependent manner. A, B Bioinformatics analysis of the possible binding sites between Miat and miR-133a. C The RIP assay and Western blot were performed to confirm whether Miat and miR-133a-3p could directly bind to Ago2 in H9c2 cells. D Anti-Ago2 RIP was performed in H9c2 cells transiently overexpressing miR-133a and followed by RT-qPCR and western blot to detect lncRNA-Miat associated with Ago2. Values are expressed as the means ± SD (n = 3), *P < 0.05, **P < 0.01

Full size image

Inhibiting the expression of CTGF through Miat-miR-133a-Ago2

In order to further explore the myocardial fibrosis regulation effect of Miat on the sponge effect of miR-133a-3p, the Targetscan website was used to predict the binding of miR-133a-3p with wild-type CTGF-3ʹUTR (Fig. 5A). Subsequently, the relationship between CTGF and miR-133a-3p was confirmed by the luciferase reporter gene assay, and compared with the CTGF-3ʹUTR (WT) + NC mimic group, the relative luciferase activity of CTGF-3ʹUTR (WT) + miR-133a-3p mimic group was significantly decreased (Fig. 5B). In addition, the mutation of CTGF-3ʹUTR eliminated its binding to miR-133a-3p, meaning that miR-133a-3p binds to the wild-type CTGF-3ʹUTR at the predicted binding site. We identified CTGF expression in H9c2 cells transfected with mir133a-3p mimic or NC mimic. The results showed that the expression level of CTGF mRNA and protein level were significantly down-regulated in the miR-133a-3p mimic group (Fig. 5C and D), indicating that the up-regulation of miR-133a-3p inhibited the expression of CTGF. A schematic outline of how the lncRNA Miat may function as a ceRNA for miR-133a-3p-Ago2, promoting the expression of CTGF protein is shown in Fig. 5E. Therefore, it can be proved that miR-133a-3p directly targets CTGF mRNA.

Fig. 5
figure 5

CTGF is a direct target of miR-133a-3p in H9c2 cells. A CTGF was predicted as a target gene of miR-133a-3p using Targetscan. B HEK293 cells were transfected with miR-133a-3p mimic and luciferase constructs of CTGF 3′-UTR (Wild Type, WT) or mutant CTGF 3′-UTR-MUT. Luciferase activity was detected 48 h after transfection. C, D H9c2 cells were transfected with miR-133a-3p mimic. The mRNA (C) and protein (D) expression levels of CTGF were determined by RT-qPCR and Western blot. E A schematic outline of how the lncRNA Miat may function as a ceRNA for miR-133a-3p-Ago2 and promote the expression of CTGF protein. Values are expressed as the means ± SD (n = 3), *P < 0.05, **P < 0.01

Full size image

LncRNA Miat binding with peroxisome proliferator-activated receptor-gamma (PPARG)

Most Miat exists in the nucleus, and the regulatory role of lncRNA Miat in the nucleus was explored. We used catRAPID [58] to predict the proteins interacting with Miat, and the results showed that PPARGc1a/1b, the coactivator of PPARG, was bound to lncRNA Miat. We further conducted a combination of PPARG and Miat using the lncPRO website [59], and the results showed that there might be a potential combination of Miat and the PPARG protein, and the predicted score was higher than the reported combination of Miat with the REDD1 protein [60] (Fig. 6B). Subsequently, RNA-IP experiments were further used to verify the combination of PPARG and Miat (Fig. 6C). Our results showed lncRNA Miat binding with the PPARG protein.

Fig. 6
figure 6

LncRNA Miat binding with the PPARG protein. A Using catRAPID program, an interaction between Miat and PPARG was predicted. B LncPro program was used to verify the combination between Miat and PPARG, while a validated combination of Miat and REDD1 was used as a control. C The combination between Miat and PPARG was detected by RNA immunoprecipitation and Western blot. Values are expressed as the means ± SD (n = 3), *P < 0.05, **P < 0.01

Full size image

Miat promotes the transcription of TGF-β1 by inhibiting the formation of heterodimer PPARG–RXRA complex

PPARG and RXRA are important heterodimers, and PPARG–RXRA has been shown to inhibit TGF-β1 gene through Zf9 dephosphorylation [61]. In order to determine whether Miat can participate in this regulatory process, we carried out knockdown and overexpression of Miat (Fig. 7A and B), and verified the activity of TGF-β1 promoter by dual-luciferase reporter gene assay. The results showed that knockdown Miat can reduce the activity of the TGF-β1 promoter, while overexpressing Miat can promote the activity of the TGF-β1 promoter (Fig. 7C). Then, in order to verify the correlation between Miat regulation of the TGF-β1 promoter activity and PPARG/RXRA, Miat was overexpressed in H9c2 cells, and co-IP assays results showed that the binding of PPARG/RXRA complex was weakened (Fig. 7D), PPARG/RXRA complex is involved in phosphorylation modification of transcription factors, for example Zf9 [61], thereby affecting the transcription capacity of TGF-β1. Based on the above results, we inferred that Miat was involved in regulating the TGF-β1 transcriptional efficiency by affecting the formation of heterodimer of PPARG/RXRA (Fig. 7E).

Fig. 7
figure 7

Miat inhibits the formation of the heterodimer PPARG–RXRA complex and promotes the transcription of TGF-β1. A Relative expression of Miat determined by RT-qPCR in H9c2 cells transfected with pcDNA3.1 or Miat overexpression vector. B RT-qPCR confirmed the down-regulation of Miat using two different siRNAs compared with the negative control (NC). C The dual-luciferase reporter assay detected the transcriptional activity of TGF-β1 with Miat overexpressing and knockdown. The values were normalized to control expression levels (n = 3). D Co-IP experiment was used to detect the binding between PPARG and RXRA with or without Miat overexpression. E Schematic illustration of the mechanism by which lncRNA-Miat acts as a decoy to weaken PPARG/RXRA interactions, inhibit TF (for example Zf9) dephosphorylation and promote the transcriptions of TGF-β1. Values are expressed as the means ± SD (n = 3), *P < 0.05, **P < 0.01

Full size image

Discussion

Due to the difference in its expression in the heart under normal and pathological conditions, Miat has recently attracted great interest among researchers [62,63,64]. Our results showed that electroacupuncture can inhibit myocardial fibrosis by reducing the expression of Miat (Fig. 8). LncRNA Miat plays a dual regulatory role during myocardial fibrosis, it acts as “sponge” and “decoy”. At the post-transcriptional level, Miat sponges miR-133a-3p and inhibits its targeting of the CTGF mRNA; the sponge effect between Miat and miR-133a-3p is based on an Ago2-dependent manner. Additionally, Miat can decoy the PPARG protein and promote the dissociation of the heterodimer PPARG and RXRA complex in the nucleus. Miat attenuates the inhibitory effect of PPARG and RXRA complexes on TGF-β1 promoter, thus promoting the TGF-β1 transcription. Above all, Miat is a very effective target to reduce myocardial fibrosis. Reducing the expression of Miat by electroacupuncture may be an effective way to inhibit myocardial fibrosis.

Fig. 8
figure 8

Schematic illustration of the mechanism by which the down-regulation of lncRNA Miat by electroacupuncture protects against myocardial fibrosis. The injection of ISO can lead to the occurrence of myocardial fibrosis and increase the expression level of Miat, which can adsorb miR-133a-3p as a sponge and increase the expression level of the CTGF protein. Miat can also be used as decoy to promote the separation of the heterodimer PPARG/RXRA and improve the transcription of TGF-β1, thus causing myocardial fibrosis. Electroacupuncture PC6 can inhibit the expression of Miat and inhibit myocardial fibrosis

Full size image

It has been reported that acupuncture can effectively inhibit the production of ET-1 and the mRNA expression of type I and III collagen [65]. Electroacupuncture at Neiguan acupoint can promote the stem cell survival and improve ischemic heart function. Electroacupuncture could become a useful approach in stem cell therapy for ischemic heart diseases [66]. In a male chimpanzee (Pan Troglodytes) diagnosed with frequent premature ventricular contracts, acupuncture and laser therapy (PC6 and HT acupoints) appeared to decrease the mean number of VPC/min in this larger state. The rat model of chronic myocardial ischemia was established by subcutaneous injection of isoproterenol (ISO) for 14 days. Electroacupuncture pretreatment promoted angiogenesis by increasing serum HIF-1α and VEGF protein expression in myocardial infarction area [67]. ISO is often used to construct models of heart disease in rats, e.g., heart failure (HF) [68], cardiac hypertrophy [69] and chronic myocardial ischemia [67]. At the same time, ISO injection and left anterior descending (LAD) ligation are commonly used to construct rat models of myocardial fibrosis [70,71,72]. Although surgical modeling such as ligation of the LAD coronary artery has been widely used, the period is short and fast, but with high mortality. Animal models of drug-induced myocardial fibrosis have good repeatability, low mortality and are relatively stable. Therefore, in this study, we use ISO to build the rat model of myocardial fibrosis.

Compared with many other easily mutated lncRNA, Miat is highly evolutionarily conserved and highly expressed in mouse brains and continuously expressed in adult human brain [30, 64]. LncRNA Miat is susceptible to a variety of harmful factors, such as angiotensin II, isoproterenol, hypoxia and infection; Miat is anomaly overexpressed in serum, plasma, blood cells and myocardial tissues under a variety of cardiovascular conditions including myocardial infarction, cardiac hypertrophy and atrial fibrillation [36, 63, 73]. Studies have shown that lncRNA can perform biological functions regardless of whether they are in the nucleus or cytoplasm [74, 75]. In the cell nucleus, lncRNA mainly regulates chromatin, transcription regulation and variable shear regulation. In the cytoplasm, the ceRNA regulation mechanism that adsorbs miRNA is mainly used to affect mRNA stability and translation regulation [76]. Miat usually acts as an endogenous spongiform that competitively binds to miRNA and thus plays an inhibitory role on mRNA [77]. For example, knockdown Miat could up-regulate the miRNA-24 expression and reduce the expression of TGF-β1 [78]. There are three binding sites of miRNA-150 in Miat, and Miat can regulate the expression of P300 through competitive binding with miRNA-150, thus regulating the occurrence of isoprenaline-induced cardiac hypertrophy [79]. Previous reports have found that Miat can sponge miRNA-133a-3p [55]. Our study further showed that Ago2 protein could simultaneously bind to Miat and miRNA-133a-3p by RNA-IP assay. In addition, after the overexpression of miRNA-133a-3p, Ago2 protein-bound Miat significantly increased, thus proving that lncRNA Miat sponges miRNA-133a-3p through an Ago2-dependent manner. In the nucleus, lncRNA can act as decoys and lure transcription factors away from the specific location. Through nuclear and cytoplasmic separation and qPCR experiments, we found that Miat is actually rich in nuclei. This also implies that Miat plays a more important regulatory role in the nucleus. PPARG is a transcription factor known to have antidiabetogenic and immune effects, and PPARG heterodimerizes with the retinoid X receptor (RXR). This complex recognizes PPAR response elements (PPRE) in promoters on target genes resulting in the regulation of gene transcription [80, 81].

It is predicted that Miat may bind to PPARG, and PPARG/RXRA heterodimer regulates TGF-β1 transcriptional activity. The research results showed that PPARG activation might trans-repress the TGF-β1 gene, thereby altering the expression of TGF-β-inducible target genes [61]. The activation of the PPARG and RXR heterodimer contributes to the gene regulation [82]. We used dual-luciferase assay to confirm that Miat was involved in regulating the transcriptional activity of TGF- β1 promoter. This regulation may be based on the fact that Miat acts as a decoy to dissociate the binding of PPARG and RXRA heterodimer and may influence the heterodimer function on the transcriptional activity of TGF-1. In the promoter region of the TGF-β1 gene, the putative binding sites for PPARG–RXRA seemed to be unactive. The TGF-β 1 gene contains DNA reaction elements that interact with Zf9 [83, 84]. The activation of PPARG–RXR has been shown to inhibit the TGF-β1 gene through Zf9 dephosphorylation [61]. We hypothesized that the overexpression of Miat reduces the binding efficiency of PPARG and RXR, thereby affecting the phosphorylated form of Zf9. Ultimately, the transcriptional efficiency of TGF-β1 is affected. LncRNA has a variety of regulatory effects, but few reports revealed that lncRNA can affect the occurrence and progression of diseases through the combination of multiple regulatory effects. Therefore, based on the above results, Miat can act as a sponge to adsorb miRNA and regulate the expression of CTGF mRNA and act as a protein decoy to regulate the transcriptional activity of TGF-β1 at chromatin level.

Conclusion

We revealed that electroacupuncture at PC6 point can inhibit the process of myocardial fibrosis by reducing the expression of lncRNA Miat. Miat can not only act as a molecular sponge to regulate the binding of miRNA-133a to CTGF mRNA, but can also act as a decoy affecting the formation of the heterodimer PPARG and RXRA protein complex. This dual regulatory effect shows the important functions of lncRNA. In future studies, more lncRNA with multiple regulatory functions will be investigated and studied. At the same time, this work provides more insights for an in-depth study of the molecular mechanism of electroacupuncture in the treatment of cardiovascular diseases.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

Miat:

Myocardial infarction associated transcript

PC6:

Neiguan point

lncRNA:

Long non-coding RNA

ISO:

Isoproterenol treated

RT-qPCR:

Real time-quantitative reverse transcription PCR

PPARG:

Peroxisome proliferative activated receptor, gamma

RXRA:

Retinoid X receptor alpha

UTR:

Untranslated region

CTGF:

Connective tissue growth factor

TGF-β1:

Transforming Growth Factor Beta 1

NF-κB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

TNF-α:

Tumor necrosis factor-α

MMP-9:

Matrix metalloprotein9

EA:

Electroacupuncture at PC6

NA:

Electroacupuncture at non-acupoint

WT:

Wildtype

MUT:

Mutation

RIP:

RNA immunoprecipitation

Co-IP:

Co-immunoprecipitation

ECG:

Electrocardiogram

miRNP:

MiRNA ribonucleoprotein complex

Ago2:

Argonaute RISC Catalytic Component 2

HIF-1α:

Hypoxia duciblefactors-1 alpha

VEGF:

Vascular endothelial growth factor

LAD:

Left anterior descending

DMEM:

Dulbecco’s modified Eagle’s medium

HE:

Hematoxylin–eosin

HRP:

Horseradish peroxidase

IHC:

Immunohistochemistry

NC:

Negative control

PBS:

Phosphate buffered saline

SD:

Standard deviation

References

  1. Alam P, Maliken BD, Jones SM, et al. Cardiac remodeling and repair: recent approaches, advancements, and future perspective. Int J Mol Sci. 2021;22(23):13104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Verheule S, Schotten U. Electrophysiological consequences of cardiac fibrosis. Cells. 2021;10(11):3220.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich). 2007;9(7):546–50.

    Article  Google Scholar 

  4. Zhang QJ, He Y, Li Y, et al. Matricellular protein Cilp1 promotes myocardial fibrosis in response to myocardial infarction. Circ Res. 2021;129(11):1021–35.

    Article  CAS  PubMed  Google Scholar 

  5. González A, Schelbert EB, Díez J, et al. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71(15):1696–706.

    Article  PubMed  Google Scholar 

  6. Webber M, Jackson SP, Moon JC, et al. Myocardial fibrosis in heart failure: anti-fibrotic therapies and the role of cardiovascular magnetic resonance in drug trials. Cardiol Ther. 2020;9(2):363–76.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Junttila MJ, Holmström L, Pylkäs K, et al. Primary myocardial fibrosis as an alternative phenotype pathway of inherited cardiac structural disorders. Circulation. 2018;137(25):2716–26.

    Article  CAS  PubMed  Google Scholar 

  8. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gyöngyösi M, Winkler J, Ramos I, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017;19(2):177–91.

    Article  PubMed  Google Scholar 

  10. Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. Mol Aspects Med. 2019;65:2–15.

    Article  CAS  PubMed  Google Scholar 

  11. Horn MA, Trafford AW. Aging and the cardiac collagen matrix: novel mediators of fibrotic remodelling. J Mol Cell Cardiol. 2016;93:175–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cowling RT, Kupsky D, Kahn AM, et al. Mechanisms of cardiac collagen deposition in experimental models and human disease. Transl Res. 2019;209:138–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Karsdal MA, Nielsen SH, Leeming DJ, et al. The good and the bad collagens of fibrosis—their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121:43–56.

    Article  CAS  PubMed  Google Scholar 

  14. Sanderson JE, Lai KB, Shum IO, et al. Transforming growth factor-beta(1) expression in dilated cardiomyopathy. Heart. 2001;86(6):701–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Budi EH, Schaub JR, Decaris M, et al. TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities. J Pathol. 2021;254(4):358–73.

    Article  CAS  PubMed  Google Scholar 

  16. Pan X, Chen Z, Huang R, et al. Transforming growth factor β1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts. PLoS ONE. 2013;8(4):e60335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hwang HS, Lee MH, Kim HA. TGF-β1-induced expression of collagen type II and ACAN is regulated by 4E-BP1, a repressor of translation. Faseb j. 2020;34(7):9531–46.

    Article  CAS  PubMed  Google Scholar 

  18. Sui X, Wei H, Wang D. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med. 2015;19(8):1773–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cao L, Chen Y, Lu L, et al. Angiotensin II upregulates fibroblast-myofibroblast transition through Cx43-dependent CaMKII and TGF-β1 signaling in neonatal rat cardiac fibroblasts. Acta Biochim Biophys Sin (Shanghai). 2018;50(9):843–52.

    Article  CAS  Google Scholar 

  20. Wang G, Wu H, Liang P, et al. Fus knockdown inhibits the profibrogenic effect of cardiac fibroblasts induced by angiotensin II through targeting Pax3 thereby regulating TGF-β1/Smad pathway. Bioengineered. 2021;12(1):1415–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ge Z, Chen Y, Wang B, et al. MFGE8 attenuates Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of TGF-β1/Smad2/3 pathway. J Mol Cell Cardiol. 2020;139:164–75.

    Article  CAS  PubMed  Google Scholar 

  22. Zhu Y, Tao H, Jin C, et al. Transforming growth factor-β1 induces type II collagen and aggrecan expression via activation of extracellular signal-regulated kinase 1/2 and Smad2/3 signaling pathways. Mol Med Rep. 2015;12(4):5573–9.

    Article  CAS  PubMed  Google Scholar 

  23. Hinz B. The extracellular matrix and transforming growth factor-β1: tale of a strained relationship. Matrix Biol. 2015;47:54–65.

    Article  CAS  PubMed  Google Scholar 

  24. Chen Z, Zhang N, Chu HY, et al. Connective tissue growth factor: from molecular understandings to drug discovery. Front Cell Dev Biol. 2020;8:593269.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol. 2010;21(2):249–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol. 2002;14(6):681–5.

    Article  CAS  PubMed  Google Scholar 

  27. Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dean RG, Balding LC, Candido R, et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem. 2005;53(10):1245–56.

    Article  CAS  PubMed  Google Scholar 

  29. Maass PG, Luft FC, Bähring S. Long non-coding RNA in health and disease. J Mol Med (Berl). 2014;92(4):337–46.

    Article  CAS  Google Scholar 

  30. Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kuehl C, Frey N. Long noncoding RNAs in heart disease. In: Backs J, Mckinsey TA, editors. Epigenetics in cardiac disease. Cham: Springer; 2016. p. 297–316.

    Chapter  Google Scholar 

  32. Zhang X, Wang W, Zhu W, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.

    Article  CAS  PubMed Central  Google Scholar 

  33. Chen Y, Li Z, Chen X, et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B. 2021;11(2):340–54.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang Y, Luo G, Zhang Y, et al. Critical effects of long non-coding RNA on fibrosis diseases. Exp Mol Med. 2018;50(1):e428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhang J, Chen M, Chen J, et al. Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. 2017. Biosci Rep. https://doi.org/10.1042/BSR20170036.

  36. Wang XM, Li XM, Song N, et al. Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction. Biomed Pharmacother. 2019;118:109208.

    Article  CAS  PubMed  Google Scholar 

  37. Yan B, Yao J, Liu JY, et al. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015;116(7):1143–56.

    Article  CAS  PubMed  Google Scholar 

  38. Zhu XH, Yuan YX, Rao SL, et al. LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci. 2016;20(17):3653–60.

    PubMed  Google Scholar 

  39. Wu Q, Han L, Yan W, et al. miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA CHRF. Sci Rep. 2016;6:30921.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Chen L, Yan KP, Liu XC, et al. Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure. Arch Pharm Res. 2018;41(1):101–9.

    Article  CAS  PubMed  Google Scholar 

  41. Liang H, Pan Z, Zhao X, et al. LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d. Theranostics. 2018;8(4):1180–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Guo M, Liu T, Zhang S, et al. RASSF1-AS1, an antisense lncRNA of RASSF1A, inhibits the translation of RASSF1A to exacerbate cardiac fibrosis in mice. Cell Biol Int. 2019;43(10):1163–73.

    Article  CAS  PubMed  Google Scholar 

  43. Zheng D, Zhang Y, Hu Y, et al. Long noncoding RNA Crnde attenuates cardiac fibrosis via Smad3-Crnde negative feedback in diabetic cardiomyopathy. FEBS J. 2019;286(9):1645–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ying W, Zhao WS, Li D, et al. The beneficial effects of electroacupuncture at PC6 acupoints (Neiguan) on myocardial ischemia in ASIC3−/− mice. J Acupunct Meridian Stud. 2018;11(3):88–96.

    Article  Google Scholar 

  45. Tsou MT, Huang CH, Chiu JH. Electroacupuncture on PC6 (Neiguan) attenuates ischemia/reperfusion injury in rat hearts. Am J Chin Med. 2004;32(6):951–65.

    Article  PubMed  Google Scholar 

  46. Yan H, Sheng FL, Chen JH, et al. Electro-acupuncture at Neiguan pretreatment alters genome-wide gene expressions and protects rat myocardium against ischemia-reperfusion. Molecules. 2014;19(10):16158–78.

    Article  CAS  Google Scholar 

  47. Zeng Q, He H, Wang XB, et al. Electroacupuncture preconditioning improves myocardial infarction injury via enhancing AMPK-dependent autophagy in rats. Biomed Res Int. 2018;2018:1238175.

    PubMed  PubMed Central  Google Scholar 

  48. Ma L, Cui B, Shao Y, et al. Electroacupuncture improves cardiac function and remodeling by inhibition of sympathoexcitation in chronic heart failure rats. Am J Physiol Heart Circ Physiol. 2014;306(10):H1464–71.

    Article  CAS  PubMed  Google Scholar 

  49. Hinderer S, Schenke-Layland K. Cardiac fibrosis—a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77–82.

    Article  CAS  PubMed  Google Scholar 

  50. Xin JJ, Dai QF, Lu FY, et al. Antihypertensive and antifibrosis effects of acupuncture at PC6 acupoints in spontaneously hypertensive rats and the underlying mechanisms. Front Physiol. 2020;11:734.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med. 2009;59(4):339–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Sun L, Luo H, Bu D, et al. Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. Nucleic Acids Res. 2013;41(17):e166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lin Y, Pan X, Shen HB. lncLocator 2.0: a cell-line-specific subcellular localization predictor for long non-coding RNAs with interpretable deep learning. Bioinformatics. 2021;37(16):2308–16.

    Article  CAS  Google Scholar 

  54. Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.

    Article  PubMed Central  Google Scholar 

  55. Yao L, Zhou B, You L, et al. LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis. Mol Biol Rep. 2020;47(4):2605–17.

    Article  CAS  PubMed  Google Scholar 

  56. Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015;22(1):22–33.

    Article  CAS  PubMed  Google Scholar 

  57. Ma MZ, Zhang Y, Weng MZ, et al. Long noncoding RNA GCASPC, a target of miR-17-3p, negatively regulates pyruvate carboxylase-dependent cell proliferation in gallbladder cancer. Cancer Res. 2016;76(18):5361–71.

    Article  CAS  PubMed  Google Scholar 

  58. Bellucci M, Agostini F, Masin M, et al. Predicting protein associations with long noncoding RNAs. Nat Methods. 2011;8(6):444–5.

    Article  CAS  PubMed  Google Scholar 

  59. Lu Q, Ren S, Lu M, et al. Computational prediction of associations between long non-coding RNAs and proteins. BMC Genomics. 2013;14:651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Guo X, Wang Y, Zheng D, et al. LncRNA-MIAT promotes neural cell autophagy and apoptosis in ischemic stroke by up-regulating REDD1. Brain Res. 2021;1763:147436.

    Article  CAS  PubMed  Google Scholar 

  61. Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol. 2006;70(1):415–25.

    Article  CAS  PubMed  Google Scholar 

  62. Yang C, Zhang Y, Yang B. MIAT, a potent CVD-promoting lncRNA. Cell Mol Life Sci. 2021;79(1):43.

    Article  PubMed  CAS  Google Scholar 

  63. Sun C, Huang L, Li Z, et al. Long non-coding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci. 2018;25(1):23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Jiang Q, Shan K, Qun-Wang X, et al. Long non-coding RNA-MIAT promotes neurovascular remodeling in the eye and brain. Oncotarget. 2016;7(31):49688–98.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Zhang YY, Liu QG, Xu M, et al. Effects of twirling-rotating reinforcing and reducing technique for left ventricular morphology, concentration of ET-1 and expression of type I, III collagen mRNA in spontaneous hypertensive rats. Zhongguo Zhen Jiu. 2014;34(8):791–7.

    CAS  PubMed  Google Scholar 

  66. Zhang J, Jia XH, Xu ZW, et al. Improved mesenchymal stem cell survival in ischemic heart through electroacupuncture. Chin J Integr Med. 2013;19(8):573–81.

    Article  CAS  PubMed  Google Scholar 

  67. Fu Y, Li J, Wu S, et al. Electroacupuncture pretreatment promotes angiogenesis via hypoxia-inducible factor 1α and vascular endothelial growth factor in a rat model of chronic myocardial ischemia. Acupunct Med. 2021;39(4):367–75.

    Article  PubMed  Google Scholar 

  68. Zhou Q, Pan LL, Xue R, et al. The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure. Theranostics. 2020;10(14):6167–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Shang L, Pin L, Zhu S, et al. Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/GSK-3β signaling pathway. Chem Biol Interact. 2019;307:21–8.

    Article  CAS  PubMed  Google Scholar 

  70. Ning BB, Zhang Y, Wu DD, et al. Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice. Acta Pharmacol Sin. 2017;38(3):331–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Zhang Y, Zhang L, Fan X, et al. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways. Biomed Pharmacother. 2019;113:108780.

    Article  CAS  PubMed  Google Scholar 

  72. Yao Y, Hu C, Song Q, et al. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc Res. 2020;116(5):956–69.

    Article  CAS  PubMed  Google Scholar 

  73. Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014;115(7):668–77.

    Article  CAS  PubMed  Google Scholar 

  74. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom Proteom Bioinform. 2016;14(1):42–54.

    Article  Google Scholar 

  76. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Ye ZM, Yang S, Xia YP, et al. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis. 2019;10(2):138.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Qu X, Du Y, Shu Y, et al. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep. 2017;7:42657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Shao X, Qin J, Wan C, et al. ADSC exosomes mediate lncRNA-MIAT alleviation of endometrial fibrosis by regulating miR-150-5p. Front Genet. 2021;12:679643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat. 2003;71(1–2):1–22.

    Article  CAS  PubMed  Google Scholar 

  81. Deng K, Ren C, Fan Y, et al. YAP1 regulates PPARG and RXR alpha expression to affect the proliferation and differentiation of ovine preadipocyte. J Cell Biochem. 2019;120(12):19578–89.

    Article  CAS  PubMed  Google Scholar 

  82. Holmbeck SM, Dyson HJ, Wright PE. DNA-induced conformational changes are the basis for cooperative dimerization by the DNA binding domain of the retinoid X receptor. J Mol Biol. 1998;284(3):533–9.

    Article  CAS  PubMed  Google Scholar 

  83. Kim SJ, Glick A, Sporn MB, et al. Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J Biol Chem. 1989;264(1):402–8.

    Article  CAS  PubMed  Google Scholar 

  84. Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem. 1998;273(50):33750–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No human studies were carried out by the authors for this article.

Funding

This work was funded by the regional cooperation program of the National Natural Science Foundation of China (No. U21A20404), National Natural Science Foundation of China (No. 82074556) and China Postdoctoral Science Foundation (No. 2020M683642XB).

Author information

Authors and Affiliations

  1. College of Acupuncture, Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, Sichuan, China

    Wenchuan Qi, Xiang Li, Yanrong Ren, Xueying Liu, Hongjuan Fu, Xiao Wang, Xiao Li, Jian Xiong, Qianhua Zheng, Dingjun Cai & Fanrong Liang

  2. College of Acupuncture, Moxibustion and Tuina, Shanxi University of Traditional Chinese Medicine, Jinzhong, 030002, Shanxi, China

    Yanrong Ren & Xueying Liu

Authors
  1. Wenchuan Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanrong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xueying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongjuan Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qianhua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dingjun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Fanrong Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

F-RL and W-CQ conceived and designed the experiments. W-CQ and XL are co-lead authors. W-CQ did most of the experiments and analyzed the data. XL helped with language polishing. H-JF, X-L and X-W helped with EMG experiments. Y-RR, H-JF, J-X and X-YL helped with the rat models. W-CQ prepared the manuscript. F-RL, D-JC and Q-HZ help with manuscript revision. All authors reviewed and revised this manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Dingjun Cai or Fanrong Liang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Committee on Ethical Use of Animals of Chengdu University of Traditional Chinese Medicine. All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the Chengdu University of Traditional Chinese Medicine.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Uncropped image of blots and gels in the article. Table S1. RT-qPCR primers and siRNA oligonucleotides used in this study.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qi, W., Li, X., Ren, Y. et al. Downregulation of lncRNA Miat contributes to the protective effect of electroacupuncture against myocardial fibrosis. Chin Med 17, 57 (2022). https://doi.org/10.1186/s13020-022-00615-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13020-022-00615-6

Keywords

  • Myocardial fibrosis
  • Electroacupuncture
  • lncRNA Miat
  • CTGF
  • TGF-β1
  • Heterodimer PPARG–RXRA

Chinese Medicine

ISSN: 1749-8546

Contact us